Table I.

Clinical and biological features of the analyzed CLL patients.

CLL	RAI stage	Age	Sex	IGHV status	CD38	ZAP70	Cytogenetics	IgM MFIR	IgD MFIR
1	IV	54	F	M	neg	neg	del 13q	3.70	1.51
2	I	60	M	U	neg	neg	del 11q, del13q	15.73	12.25
3	III	48	M	M	neg	pos	del 13q	60.92	85.48
4	IV	50	M	M	neg	pos	neg	11.36	24.22
5	I	74	M	U	pos	pos	del 13q	71.99	90.55
6	I	83	F	U	neg	pos	del13q, del17p	37.83	9.18
7	0	67	F	M	neg	nd	del 13q	26.35	30.10
8	I	53	M	M	neg	neg	del 13q	30.74	15.70
9	0	68	M	M	neg	nd	del 13q	19.30	26.20
10	III	56	M	U	neg	pos	neg	59.53	36.77
11	I	54	M	M	neg	nd	del 13q	87.03	49.12
12	0	49	M	M	neg	nd	del 13q	8.02	11.22
13	III	70	M	M	pos	neg	neg	43.28	14.89
14	0	55	M	U	neg	pos	nd	100.51	109.15
15	0	72	F	M	neg	nd	nd	34.76	13.33
16	0	62	M	M	neg	neg	del 13q	19.65	22.73
17	0	45	F	U	neg	pos	tri 12	91.12	38.99
18	I	71	M	M	neg	nd	del 13q	85.44	62.49
19	I	64	F	M	neg	neg	neg	18.80	37.80
20	II	68	M	U	pos	pos	neg	224.66	89.91
21	I	40	M	M	nd	nd	del 13q	67.78	91.71
22	0	54	F	M	neg	neg	del 13q	35.22	31.17
23	IV	63	M	M	neg	neg	del 13q	28.66	6.14
24	I	80	F	U	neg	pos	del 13q	83.39	44.07
25	I	60	M	U	pos	pos	del 13q, del17p	145.92	21.05
26	I	73	M	U	nd	pos	del13q	113.18	23.18
27	I	55	F	U	neg	pos	neg	43.01	30.56
28	I	52	F	U	pos	pos	neg	45.00	91.67
29	I	70	F	M	nd	nd	del 13q	10.19	3.86
30	II	73	M	U	nd	nd	nd	75.83	30.45
31	0	69	F	M	neg	neg	tri12, del 13q	53.32	21.87
32	II	70	F	U	neg	pos	tri 12, del 13q, del 17p	111.78	166.79
33	III	73	F	M	pos	nd	neg	35.24	108.99
34	I	72	F	M	pos	neg	neg	10.06	23.73
35	0	66	M	M	pos	neg	tri12	1.60	1.90
36	0	69	F	M	nd	nd	nd	17.33	52.36
37	0	55	M	U	pos	nd	tri12	123.70	91.34
38	III	58	M	U	nd	nd	nd	277.85	52.43
39	II	67	M	U	pos	pos	del 11q, del13q	96.46	72.54
40	IV	66	F	U	pos	nd	del13q	130.37	133.63
41	I	59	M	M	nd	neg	del13q	20.82	51.30
42	0	70	F	M	nd	nd	neg	23.96	66.12
43	0	61	F	M	neg	neg	del13q	29.65	26.44
44	I	71	F	M	pos	neg	neg	10.06	23.73
45	I	66	F	M	neg	nd	neg	39.54	23.18
46	IV	54	M	M	neg	neg	del11q, del13q	191.78	24.07
47	I	80	F	M	nd	nd	del13q	18.43	8.45
48	II	79	M	M	neg	pos	del13q	39.01	31.87
49	I	55	F	M	neg	neg	neg	47.75	89.53
50	I	58	F	M	neg	pos	del13q	35.18	18.06
51	IV	62	M	M	neg	neg	del13q	7.36	2.15
52	I	71	M	M	neg	nd	del13q	48.57	29.67
53	I	68	M	M	pos	nd	tri12, del13q	1.20	1.39
54	0	56	F	U	pos	pos	del13q	90.45	113.44
55	II	61	F	U	neg	nd	del11q, del13q	89.40	158.21
56	I	59	F	U	neg	pos	tri12	26.96	24.72
57	I	57	M	U	neg	pos	del11q, del13q	8.49	11.89
58	I	59	M	U	pos	nd	del13q	121.86	55.98
59	I	40	M	U	neg	nd	del13q	51.84	27.08
60	IV	65	M	U	pos	pos	del11q	55.64	34.26
61	0	66	M	U	pos	nd	del11q	10.31	2.86
62	I	62	F	M	neg	neg	neg	14.40	33.10
63	I	67	F	M	neg	nd	del13q	65.13	43.59
64	II	63	M	M	pos	nd	tri12	7.79	4.47
65	I	61	F	M	neg	neg	neg	72.60	93.72
66	0	64	M	M	neg	nd	neg	13.75	60.00
67	0	54	F	U	neg	pos	del13q	71.73	38.17
68	II	68	M	U	neg	pos	tri12	113.29	98.24
69	0	66	M	U	neg	pos	del13q	61.73	42.64
70	I	66	F	U	nd	nd	tri12	57.90	78.08
71	0	67	M	U	neg	neg	neg	35.02	26.39
72	I	63	F	U	neg	pos	del17p	106.88	7.29
73	I	62	M	U	pos	neg	del 11q, del13q	179.83	8.67
74	I	72	M	U	neg	neg	del 11q, del13q	64.40	59.06
75	I	76	F	U	nd	nd	nd	42.55	18.78
76	I	74	F	U	neg	nd	tri12	136.16	54.88
77	II	77	F	U	nd	nd	del13q	143.19	68.98
78	I	54	M	M	neg	neg	del13q	53.58	28.48
79	I	73	M	M	pos	pos	tri 12	28.73	41.83
80	I	60	F	U	neg	neg	del11q, del13q	22.59	33.39
81	I	60	M	U	pos	pos	tri12	78.86	84.12
82	I	58	F	U	neg	pos	del13q	76.67	34.31
83	I	69	M	U	neg	pos	del11q, del17p	57.82	25.21
84	I	66	M	U	pos	nd	del13q	51.12	54.92

Rai stage of disease, age at diagnosis, sex, Immunoglobulin Heavy Chain Variable region (IGHV) gene mutational status (M: M-CLL; U: U-CLL), CD38 expression (pos: positive; neg: negative), ZAP70 expression (pos:positive; neg:negative), cytogenetic abnormalities (del: deletion; tri: trisomy; neg: no abnormalities), and mean fluorescent intensity ratios (MFIR) of IgM and IgD BCRs. IGHV gene mutational analysis was performed by PCR followed by direct sequencing and 98% cut-off was used for mutational status assessment. CD38 expression was determined by flow cytometry and 30% positivity was used as cut-off. ZAP70 expression was evaluated by immunohistochemical staining of bone marrow biopsies. Cytogenetic abnormalities were determined by FISH analysis. nd: not determined. IgM and IgD levels were determined by flow cytometry.